Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 10 | 2024 | 114 | 4.210 |
Why?
|
| Cardiovascular Diseases | 9 | 2025 | 788 | 3.230 |
Why?
|
| Albuminuria | 4 | 2025 | 28 | 2.820 |
Why?
|
| Diabetic Nephropathies | 6 | 2023 | 37 | 2.660 |
Why?
|
| Mortality | 3 | 2024 | 155 | 2.380 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 3 | 2024 | 6 | 2.100 |
Why?
|
| Kidney Failure, Chronic | 4 | 2025 | 206 | 1.960 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 635 | 1.760 |
Why?
|
| Hyponatremia | 3 | 2022 | 13 | 1.680 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 192 | 1.680 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 205 | 1.660 |
Why?
|
| Kidney | 7 | 2025 | 416 | 1.620 |
Why?
|
| Nutrition Surveys | 4 | 2024 | 129 | 1.490 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 101 | 1.420 |
Why?
|
| Kidney Diseases | 4 | 2025 | 169 | 1.410 |
Why?
|
| Betacoronavirus | 3 | 2020 | 166 | 1.350 |
Why?
|
| Biomarkers | 6 | 2025 | 1306 | 1.210 |
Why?
|
| Pandemics | 4 | 2020 | 615 | 1.140 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 132 | 1.070 |
Why?
|
| Amyloidosis | 2 | 2024 | 62 | 1.070 |
Why?
|
| Humans | 48 | 2025 | 59360 | 1.000 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2022 | 12 | 0.930 |
Why?
|
| Metabolic Diseases | 1 | 2025 | 54 | 0.910 |
Why?
|
| Adiposity | 1 | 2024 | 74 | 0.900 |
Why?
|
| Creatinine | 5 | 2024 | 128 | 0.850 |
Why?
|
| Neoplasms | 3 | 2023 | 1240 | 0.850 |
Why?
|
| Water Intoxication | 1 | 2022 | 1 | 0.820 |
Why?
|
| Polydipsia, Psychogenic | 1 | 2022 | 1 | 0.820 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 122 | 0.800 |
Why?
|
| Resuscitation | 1 | 2023 | 69 | 0.800 |
Why?
|
| Metabolic Syndrome | 1 | 2023 | 131 | 0.800 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 163 | 0.730 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 313 | 0.730 |
Why?
|
| Naphthyridines | 1 | 2021 | 6 | 0.730 |
Why?
|
| Coronavirus | 1 | 2020 | 12 | 0.710 |
Why?
|
| Risk Factors | 9 | 2025 | 4984 | 0.710 |
Why?
|
| ADAM17 Protein | 1 | 2020 | 9 | 0.700 |
Why?
|
| Adult | 17 | 2025 | 15669 | 0.680 |
Why?
|
| Lactic Acid | 1 | 2020 | 71 | 0.680 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 64 | 0.660 |
Why?
|
| Renal Dialysis | 3 | 2018 | 189 | 0.650 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 142 | 0.640 |
Why?
|
| Diabetes Mellitus | 3 | 2025 | 515 | 0.630 |
Why?
|
| Heart Failure | 3 | 2023 | 853 | 0.620 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 162 | 0.620 |
Why?
|
| Renal Insufficiency | 2 | 2024 | 65 | 0.620 |
Why?
|
| Incidence | 5 | 2024 | 1237 | 0.620 |
Why?
|
| Hypertension | 3 | 2025 | 568 | 0.520 |
Why?
|
| Disease Progression | 6 | 2024 | 1122 | 0.520 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2020 | 42 | 0.510 |
Why?
|
| Aged | 16 | 2025 | 13416 | 0.510 |
Why?
|
| Middle Aged | 15 | 2025 | 16317 | 0.510 |
Why?
|
| Female | 22 | 2025 | 30705 | 0.500 |
Why?
|
| Prospective Studies | 7 | 2024 | 3067 | 0.490 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 15 | 0.470 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 43 | 0.470 |
Why?
|
| Male | 19 | 2025 | 27739 | 0.460 |
Why?
|
| Patient Preference | 1 | 2015 | 78 | 0.450 |
Why?
|
| Bleaching Agents | 1 | 2013 | 6 | 0.420 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 364 | 0.420 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 12 | 0.420 |
Why?
|
| Republic of Korea | 2 | 2024 | 29 | 0.410 |
Why?
|
| Prognosis | 4 | 2024 | 1600 | 0.400 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 34 | 0.400 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2022 | 4 | 0.390 |
Why?
|
| Patient Safety | 1 | 2015 | 237 | 0.390 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 246 | 0.390 |
Why?
|
| Hyperoxaluria | 2 | 2024 | 8 | 0.380 |
Why?
|
| Cause of Death | 2 | 2024 | 210 | 0.380 |
Why?
|
| Puerperal Disorders | 1 | 2011 | 14 | 0.380 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2011 | 12 | 0.370 |
Why?
|
| Cohort Studies | 5 | 2025 | 2374 | 0.370 |
Why?
|
| Machine Learning | 2 | 2024 | 153 | 0.360 |
Why?
|
| Mother-Child Relations | 1 | 2011 | 43 | 0.350 |
Why?
|
| Signal Transduction | 1 | 2020 | 2902 | 0.340 |
Why?
|
| Risk Assessment | 3 | 2024 | 1921 | 0.330 |
Why?
|
| United States | 4 | 2024 | 7390 | 0.310 |
Why?
|
| Pneumonia | 1 | 2011 | 281 | 0.290 |
Why?
|
| Albumins | 2 | 2024 | 34 | 0.280 |
Why?
|
| Recovery of Function | 3 | 2024 | 270 | 0.270 |
Why?
|
| Communication | 1 | 2011 | 545 | 0.260 |
Why?
|
| Aldosterone | 2 | 2022 | 17 | 0.250 |
Why?
|
| Potassium | 2 | 2022 | 100 | 0.250 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2024 | 17 | 0.240 |
Why?
|
| Nephrologists | 1 | 2024 | 7 | 0.240 |
Why?
|
| Waist Circumference | 1 | 2024 | 45 | 0.230 |
Why?
|
| Osteopontin | 1 | 2024 | 22 | 0.230 |
Why?
|
| Stroke | 2 | 2024 | 1127 | 0.230 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 20 | 0.220 |
Why?
|
| Time Factors | 2 | 2024 | 3617 | 0.220 |
Why?
|
| Angiotensins | 2 | 2020 | 4 | 0.220 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 69 | 0.220 |
Why?
|
| Device Removal | 1 | 2024 | 64 | 0.220 |
Why?
|
| Atrial Appendage | 1 | 2024 | 29 | 0.220 |
Why?
|
| Kidney Glomerulus | 1 | 2023 | 21 | 0.220 |
Why?
|
| Aphasia | 1 | 2024 | 42 | 0.220 |
Why?
|
| Cystatin C | 1 | 2023 | 8 | 0.210 |
Why?
|
| Fluid Therapy | 1 | 2023 | 47 | 0.200 |
Why?
|
| Apolipoprotein L1 | 1 | 2022 | 6 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 1 | 2023 | 137 | 0.200 |
Why?
|
| Proteomics | 1 | 2024 | 263 | 0.200 |
Why?
|
| Canagliflozin | 1 | 2022 | 5 | 0.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 6 | 0.200 |
Why?
|
| Body Mass Index | 2 | 2024 | 831 | 0.200 |
Why?
|
| India | 2 | 2024 | 150 | 0.190 |
Why?
|
| Young Adult | 2 | 2024 | 4267 | 0.190 |
Why?
|
| Models, Immunological | 1 | 2022 | 85 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2337 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2024 | 716 | 0.190 |
Why?
|
| Patient Selection | 1 | 2024 | 464 | 0.190 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 21 | 0.180 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hypophosphatemia, Familial | 1 | 2020 | 5 | 0.180 |
Why?
|
| Nephrolithiasis | 1 | 2020 | 8 | 0.180 |
Why?
|
| Ascites | 1 | 2020 | 21 | 0.180 |
Why?
|
| Glucosides | 1 | 2020 | 13 | 0.170 |
Why?
|
| Ions | 1 | 2020 | 52 | 0.170 |
Why?
|
| Osmolar Concentration | 1 | 2020 | 88 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 705 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2022 | 146 | 0.170 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 67 | 0.170 |
Why?
|
| Diuretics | 1 | 2020 | 59 | 0.170 |
Why?
|
| Vasodilation | 1 | 2020 | 35 | 0.170 |
Why?
|
| Lung Injury | 1 | 2020 | 32 | 0.170 |
Why?
|
| Drainage | 1 | 2020 | 149 | 0.170 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 48 | 0.170 |
Why?
|
| Drug Discovery | 1 | 2020 | 89 | 0.160 |
Why?
|
| Immunity | 1 | 2020 | 101 | 0.160 |
Why?
|
| Virus Internalization | 1 | 2020 | 81 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 146 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2373 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 674 | 0.150 |
Why?
|
| Calcium | 1 | 2022 | 555 | 0.150 |
Why?
|
| Maternal Mortality | 1 | 2018 | 12 | 0.150 |
Why?
|
| Infant Mortality | 1 | 2018 | 19 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5284 | 0.150 |
Why?
|
| Pregnancy | 2 | 2018 | 2202 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 677 | 0.140 |
Why?
|
| Gene Expression | 1 | 2020 | 809 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5128 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2018 | 365 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 862 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 181 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 805 | 0.130 |
Why?
|
| Comorbidity | 2 | 2025 | 1078 | 0.120 |
Why?
|
| Algorithms | 1 | 2020 | 976 | 0.120 |
Why?
|
| Vascular Grafting | 1 | 2015 | 39 | 0.120 |
Why?
|
| Coronary Disease | 2 | 2012 | 244 | 0.110 |
Why?
|
| Prevalence | 1 | 2018 | 1252 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2015 | 102 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1283 | 0.110 |
Why?
|
| Infant | 1 | 2018 | 1486 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 155 | 0.100 |
Why?
|
| Patient Participation | 1 | 2015 | 216 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1479 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 251 | 0.100 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 105 | 0.100 |
Why?
|
| Oxalates | 2 | 2024 | 17 | 0.100 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 2011 | 52 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1166 | 0.090 |
Why?
|
| Child | 1 | 2020 | 4174 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 206 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 1526 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2012 | 300 | 0.080 |
Why?
|
| Patients | 1 | 2011 | 103 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 451 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 687 | 0.070 |
Why?
|
| Health Promotion | 1 | 2011 | 471 | 0.070 |
Why?
|
| Mice | 1 | 2020 | 10292 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 724 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6071 | 0.060 |
Why?
|
| United Kingdom | 1 | 2025 | 69 | 0.060 |
Why?
|
| Biological Specimen Banks | 1 | 2025 | 19 | 0.060 |
Why?
|
| Tenascin | 1 | 2024 | 4 | 0.060 |
Why?
|
| Kidney Tubules | 1 | 2024 | 18 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2024 | 75 | 0.060 |
Why?
|
| Aortography | 1 | 2024 | 55 | 0.060 |
Why?
|
| Curcuma | 1 | 2024 | 2 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2024 | 58 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 91 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 30 | 0.050 |
Why?
|
| Embolism | 1 | 2024 | 39 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 113 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2024 | 209 | 0.050 |
Why?
|
| Proteinuria | 1 | 2023 | 38 | 0.050 |
Why?
|
| Urea | 1 | 2022 | 35 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 60 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 252 | 0.050 |
Why?
|
| Adolescent | 1 | 2013 | 5824 | 0.050 |
Why?
|
| Animals | 1 | 2020 | 19651 | 0.050 |
Why?
|
| Renal Elimination | 1 | 2022 | 3 | 0.050 |
Why?
|
| Thrombosis | 1 | 2024 | 182 | 0.050 |
Why?
|
| Biopsy | 1 | 2023 | 411 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2024 | 223 | 0.050 |
Why?
|
| Phosphorus | 1 | 2020 | 16 | 0.040 |
Why?
|
| Renin | 1 | 2020 | 10 | 0.040 |
Why?
|
| Genotype | 1 | 2022 | 617 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 555 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 35 | 0.040 |
Why?
|
| Transcriptome | 1 | 2023 | 340 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 246 | 0.040 |
Why?
|
| Sex Factors | 1 | 2022 | 935 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 441 | 0.040 |
Why?
|
| Brain | 1 | 2024 | 1488 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 1099 | 0.030 |
Why?
|
| Cholesterol | 1 | 2011 | 252 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 495 | 0.020 |
Why?
|
| Smoking | 1 | 2011 | 826 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 883 | 0.010 |
Why?
|